SMS Pharmaceuticals Ltd

SMS Pharma. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

SMS Pharmaceuticals Ltd

₹ 214 5.35%
21 Feb - close price
smspharma.com BSE: 532815 NSE: SMSPHARMA
About

SMS Pharmaceuticals Ltd is a diversified and integrated pharmaceutical company with interests in Active Pharmaceutical Ingredients (API) and Intermediates.[1]

Key Points

Product Portfolio
It is an integrated pharmaceutical company specializing in Active Pharmaceutical Ingredients (API) and complex Intermediates, under various therapeutic categories including Anti-ulcer, anti-fungal, anti-migraine, anti-viral, anti-diabetic, anti-retroviral, etc. with global leadership position in 10+ therapeutic products. The company offers 45+ products to 800+ customers across 75+ countries. [1] [2]

Website BSE NSE
  • Market Cap ₹ 1,816 Cr.
  • Current Price ₹ 214
  • High / Low ₹ 398 / 140
  • Stock P/E 27.5
  • Book Value ₹ 66.5
  • Dividend Yield 0.19 %
  • ROCE 11.7 %
  • ROE 9.99 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company is expected to give good quarter

Cons

  • Stock is trading at 3.22 times its book value
  • The company has delivered a poor sales growth of 8.81% over past five years.
  • Company has a low return on equity of 7.48% over last 3 years.
  • Debtor days have increased from 86.4 to 122 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Part of BSE Healthcare BSE Allcap BSE SmallCap

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
121 61 64 159 149 149 135 167 161 246 164 197 173
94 65 65 146 130 126 109 139 132 212 131 165 140
Operating Profit 27 -4 -1 14 19 23 26 28 29 34 34 31 33
OPM % 22% -7% -1% 9% 12% 16% 19% 17% 18% 14% 20% 16% 19%
2 0 1 1 2 1 1 1 1 2 1 1 2
Interest 5 4 5 5 6 6 6 6 6 6 5 5 4
Depreciation 8 8 8 8 8 8 8 8 8 8 8 9 9
Profit before tax 16 -16 -13 1 7 11 13 15 17 22 22 20 22
Tax % 37% -154% -20% 13% 21% 24% 31% 21% 26% 26% 25% 29% 24%
9 6 -13 -2 4 6 9 12 11 17 16 14 18
EPS in Rs 1.06 0.73 -1.51 -0.24 0.44 0.73 1.10 1.38 1.36 2.04 1.95 1.66 2.15
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2007 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
193 611 438 463 465 412 563 520 522 709 780
145 522 363 369 375 332 442 405 467 593 649
Operating Profit 47 89 75 93 90 80 121 115 55 117 132
OPM % 25% 15% 17% 20% 19% 19% 22% 22% 10% 16% 17%
5 4 1 2 3 5 3 5 5 4 6
Interest 8 17 16 15 12 12 11 19 22 24 19
Depreciation 5 19 19 20 19 22 22 32 32 32 34
Profit before tax 40 56 42 60 62 51 91 68 5 66 86
Tax % 36% 26% 14% 33% 34% 36% 33% 1% 28% 26%
25 41 28 32 40 32 63 62 -7 50 66
EPS in Rs 2.55 4.83 3.36 3.75 4.73 3.73 7.38 7.35 -0.83 5.88 7.80
Dividend Payout % 8% 4% 6% 7% 5% 7% 4% 4% -36% 7%
Compounded Sales Growth
10 Years: %
5 Years: 9%
3 Years: 8%
TTM: 27%
Compounded Profit Growth
10 Years: %
5 Years: 4%
3 Years: -7%
TTM: 70%
Stock Price CAGR
10 Years: 18%
5 Years: 42%
3 Years: 31%
1 Year: 51%
Return on Equity
10 Years: %
5 Years: 9%
3 Years: 7%
Last Year: 10%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2007 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 10 8 8 8 8 8 8 8 8 8 8
Reserves 182 285 246 276 313 340 402 462 452 528 555
73 204 149 146 144 157 255 263 254 281 285
64 158 89 72 93 103 147 126 165 217 286
Total Liabilities 329 656 493 503 559 608 812 860 880 1,034 1,135
69 370 290 279 281 280 457 438 412 437 426
CWIP 15 13 8 8 18 42 7 11 33 30 94
Investments 0 21 29 28 27 26 27 22 11 11 11
245 252 166 187 232 259 321 389 424 556 603
Total Assets 329 656 493 503 559 608 812 860 880 1,034 1,135

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2007 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
14 61 73 32 50 40 90 45 22 50
-32 -97 -39 -17 -35 -43 -152 -27 -30 -52
107 27 -33 -15 -13 -2 92 -12 -32 31
Net Cash Flow 89 -9 1 0 2 -5 31 6 -39 29

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2007 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 114 36 18 19 20 43 68 34 104 122
Inventory Days 165 106 114 135 170 191 148 333 243 201
Days Payable 72 79 82 49 59 66 70 97 117 130
Cash Conversion Cycle 206 63 50 105 131 169 146 270 230 192
Working Capital Days 169 63 48 73 95 111 115 172 196 167
ROCE % 13% 18% 17% 13% 17% 13% 4% 12%

Shareholding Pattern

Numbers in percentages

Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
67.29% 64.17% 64.17% 64.17% 64.29% 64.32% 64.32% 64.32% 64.67% 64.67% 64.67% 64.67%
0.61% 0.63% 0.59% 0.59% 0.59% 0.67% 0.60% 0.59% 0.17% 0.18% 0.52% 0.31%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.98% 2.13% 2.55% 2.55%
32.10% 35.20% 35.23% 35.23% 35.12% 35.01% 35.07% 35.10% 33.18% 33.03% 32.27% 32.47%
No. of Shareholders 27,51626,63826,49126,52625,53724,65325,24625,34130,14031,78033,13634,973

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls